Cargando…
Promoterless, Nuclease‐Free Genome Editing Confers a Growth Advantage for Corrected Hepatocytes in Mice With Methylmalonic Acidemia
BACKGROUND AND AIMS: Adeno‐associated viral (AAV) gene therapy has shown great promise as an alternative treatment for metabolic disorders managed using liver transplantation, but remains limited by transgene loss and genotoxicity. Our study aims to test an AAV vector with a promoterless integrating...
Autores principales: | Chandler, Randy J., Venturoni, Leah E., Liao, Jing, Hubbard, Brandon T., Schneller, Jessica L., Hoffmann, Victoria, Gordo, Susana, Zang, Shengwen, Ko, Chih‐Wei, Chau, Nelson, Chiang, Kyle, Kay, Mark A., Barzel, Adi, Venditti, Charles P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252383/ https://www.ncbi.nlm.nih.gov/pubmed/32976669 http://dx.doi.org/10.1002/hep.31570 |
Ejemplares similares
-
In vivo genome editing at the albumin locus to treat methylmalonic acidemia
por: Schneller, Jessica L., et al.
Publicado: (2021) -
Central nervous system-targeted adeno-associated virus gene therapy in methylmalonic acidemia
por: May, Francis J., et al.
Publicado: (2021) -
Promoterless gene targeting without nucleases ameliorates haemophilia B in mice
por: Barzel, A., et al.
Publicado: (2014) -
Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia
por: An, Ding, et al.
Publicado: (2017) -
Promoterless gene targeting without nucleases rescues lethality of a Crigler‐Najjar syndrome mouse model
por: Porro, Fabiola, et al.
Publicado: (2017)